VTR
49
-3
CAG
30
4
NTAP
64
2
HUM
48
6
EW
37
-2
EXC
54
-2
C
58
-2
RRC
63
3
SWK
56
-2
MTCH
37
7
IP
70
2
CVX
46
5
DLTR
34
-4
JNPR
46
3
AMGN
44
5
DE
46
3
COF
55
-3
ALLE
37
5
PRU
57
-3
NOV
58
3
VTR
49
-3
CAG
30
4
NTAP
64
2
HUM
48
6
EW
37
-2
EXC
54
-2
C
58
-2
RRC
63
3
SWK
56
-2
MTCH
37
7
IP
70
2
CVX
46
5
DLTR
34
-4
JNPR
46
3
AMGN
44
5
DE
46
3
COF
55
-3
ALLE
37
5
PRU
57
-3
NOV
58
3
Financhill
Back

Iovance Biotherapeutics 10K Form

Sell
32

IOVA
Iovance Biotherapeutics

Last Price:
8.26
Seasonality Move:
16.76%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive IOVA News And Ratings

See the #1 stock for the next 7 days that we like better than IOVA

IOVA Financial Statistics

Sales & Book Value

Annual Sales: $1.19M
Cash Flow: $-61.26M
Price / Cash Flow: 0
Annual Sales: $2.54
Price / Book: 3.32

Profitability

EPS (TTM): -1.49000
Net Income (TTM): $-410M
Gross Margin: $-9.57M
Return on Equity: -58.9%
Return on Assets: -45.99%

Iovance Biotherapeutics Earnings Forecast

Key Iovance Biotherapeutics Financial Ratios

  • The Gross Profit Margin over the past 16 years for IOVA is -804.54%.
  • The Selling, General & Administrative Expenses for IOVA have been equal to 8,992.09% of Gross Profit Margin.
  • The Research & Development expenses have been 28,938.35% of Revenue.
  • The Interest Expense is -73.16% of Operating Income.
  • Per Share Earnings over the last 16 years have been positive in 7 years.

Iovance Biotherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: IOVA
CUSIP: 462260
Website: iovance.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.22
Quick Ratio: 3.84

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

IOVA Technical Analysis vs Fundamental Analysis

Sell
32
Iovance Biotherapeutics (IOVA) is a Sell

Is Iovance Biotherapeutics a Buy or a Sell?